HC Wainwright Research Analysts Reduce Earnings Estimates for Context Therapeutics Inc. (NASDAQ:CNTX)

Context Therapeutics Inc. (NASDAQ:CNTX) – Stock analysts at HC Wainwright lowered their FY2024 earnings estimates for Context Therapeutics in a report issued on Wednesday, November 1st. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($0.84) for the year, down from their prior forecast of ($0.56). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Context Therapeutics’ current full-year earnings is ($1.30) per share. HC Wainwright also issued estimates for Context Therapeutics’ FY2025 earnings at ($0.54) EPS, FY2026 earnings at ($0.47) EPS and FY2027 earnings at ($0.36) EPS.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings data on Wednesday, August 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.11).

Separately, Maxim Group initiated coverage on shares of Context Therapeutics in a research report on Monday, September 11th. They set a “buy” rating and a $4.00 price target on the stock.

Context Therapeutics Price Performance

CNTX opened at $1.25 on Friday. The company’s 50-day moving average is $1.13 and its 200 day moving average is $1.06. Context Therapeutics has a fifty-two week low of $0.47 and a fifty-two week high of $1.69. The firm has a market capitalization of $19.96 million, a P/E ratio of -1.07 and a beta of 2.51.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Two Sigma Investments LP raised its holdings in Context Therapeutics by 109.9% in the 1st quarter. Two Sigma Investments LP now owns 55,688 shares of the company’s stock worth $31,000 after purchasing an additional 29,154 shares during the period. State Street Corp boosted its holdings in Context Therapeutics by 79.8% in the third quarter. State Street Corp now owns 32,907 shares of the company’s stock valued at $37,000 after purchasing an additional 14,607 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Context Therapeutics during the 4th quarter worth about $38,000. Renaissance Technologies LLC raised its position in shares of Context Therapeutics by 47.4% during the 2nd quarter. Renaissance Technologies LLC now owns 28,300 shares of the company’s stock worth $45,000 after purchasing an additional 9,100 shares during the last quarter. Finally, Northern Trust Corp acquired a new stake in shares of Context Therapeutics during the 2nd quarter worth approximately $49,000. Institutional investors own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.